Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
about
Levomilnacipran for the treatment of major depressive disorder: a reviewDisposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.Levomilnacipran: a newly approved drug for treatment of major depressive disorder.Cardiovascular adverse effects of newer antidepressants.Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder.The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.Efficacy of levomilnacipran extended release in treating major depressive disorder.Consensus statements on the clinical understanding and use of milnacipran in Hong Kong.The Black Book of Psychotropic Dosing and Monitoring.Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
P2860
Q28083216-089DEE8C-5F75-4879-911F-69C7BE3FFB83Q35794456-0CCD699F-9398-4DDF-9087-1E08CAFA924DQ36781720-A272F5F6-1E32-4389-A24C-1A9AAA4BF400Q37651165-8F4AE0AB-3C3E-487C-8FB9-965BE062087FQ38187697-EB5CD722-B470-4BC9-9682-73B0B695DAD4Q38205025-7F0B8394-06EC-4324-A0B6-2A3BD590EE65Q38255663-45A459ED-4CA1-452B-8789-FE7AA069AA4FQ39207094-613B8CB3-2752-4B9B-A4E0-107918F88577Q47141387-FC7AA7DD-12B8-4BBD-A728-3B2EDD7A5E2EQ47303967-5F8772C4-EE5A-4ED5-B892-F86F32EC4B8CQ47555021-9A9817AB-7E52-414A-9027-F74BAE377996Q47642128-BEAF3EF5-E619-4276-AE97-B1F0164BECD1Q47882128-27E0547D-3382-4113-807D-543260FAE872Q48298082-27574675-455F-42BC-B477-7830BEEAE395Q50571111-D878A5E3-BCE0-4585-A34A-60F776DCF9CA
P2860
Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and tolerability of lev ...... abel, 48-week extension study.
@en
Safety and tolerability of lev ...... abel, 48-week extension study.
@nl
type
label
Safety and tolerability of lev ...... abel, 48-week extension study.
@en
Safety and tolerability of lev ...... abel, 48-week extension study.
@nl
prefLabel
Safety and tolerability of lev ...... abel, 48-week extension study.
@en
Safety and tolerability of lev ...... abel, 48-week extension study.
@nl
P2093
P2860
P1476
Safety and tolerability of lev ...... abel, 48-week extension study.
@en
P2093
Carl Gommoll
Changzheng Chen
Giovanna Forero
Rajnish Mago
William M Greenberg
P2860
P304
P356
10.1007/S40261-013-0126-5
P577
2013-10-01T00:00:00Z